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SUSTAINED EXPRESSION WITH PARTIAL CORRECTION OF NEUTROPHIL 
DEFECTS 5 YEARS AFTER INTRAMUSCULAR rAAV1 GENE THERAPY FOR ALPHA-
1 ANTITRYPSIN DEFICIENCY.  
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Alpha-1 antitrypsin (AAT) deficiency is a common monogenic disorder resulting in 
emphysema, which is currently treated with weekly infusions of protein replacement.  We 
previously reported achieving plasma wild-type (M) AAT concentrations at 2.5-3.8% of 
the therapeutic level at 1 year after intramuscular (IM) administration of 6×1012vg/kg of a 
recombinant adeno-associated virus serotype 1 (rAAV1)-AAT vector in AAT-deficient 
patients, with an associated regulatory T cell (Treg) response to AAV1 capsid epitopes 
in the absence of any exogenous immune suppression.  Here, we report sustained 
expression at greater than 2% of the therapeutic level for 5 years after one-time 
treatment with rAAV1-AAT in an AAT-deficient patient from that study, with partial 
correction of neutrophil defects previously reported in AAT-deficient patients.  There was 
also evidence of an active Treg response (FoxP3+, Helios+) and an exhausted cytotoxic 
T cell response (PD-1+, LAG-3+) to AAV1 capsid. These findings suggest that muscle-
based AAT gene replacement is toleragenic and that very stable levels of M AAT may 
exert beneficial effects at lower concentrations than previously anticipated.  
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